Cardiometabolic Diseases clinical trials

Explore recruiting cardiometabolic diseases clinical trials.

Recruiting cardiometabolic diseases studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiometabolic Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Cardiometabolic Diseases trials by city

Cardiometabolic Diseases clinical trials

Recruiting cardiometabolic diseases studies right now

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

Telenutrition for Individuals With SCI

Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study

Randomized Trial of SGLT2i in Heart Transplant Recipients

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Cardiometabolic Consequences of the Loss of Ovarian Function

Nutrition Counselling for Cardiometabolic Multimorbidity

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

Also recruiting in Europe

A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

Cardiometabolic Diseases trials by city

Other conditions